| Market Capitalization (Millions $) |
270 |
| Shares
Outstanding (Millions) |
39 |
| Employees |
471 |
| Revenues (TTM) (Millions $) |
135 |
| Net Income (TTM) (Millions $) |
-48 |
| Cash Flow (TTM) (Millions $) |
31 |
| Capital Exp. (TTM) (Millions $) |
3 |
Quanterix Corporation
Quanterix Corp is a biotech company that focuses on the development and commercialization of ultra-sensitive digital biomarker analysis solutions.
The company was founded in 2007 by David Walt, who is a pioneer in microarray technology.
Quanterix Corp aims to revolutionize the way diseases are detected and measured by providing accurate and precise biomarker measurements that can help diagnose and treat diseases at an earlier stage.
The company's flagship product is the Simoa system, which is a fully automated digital immunoassay platform that can detect and measure low-abundance biomolecules with unprecedented sensitivity.
Simoa uses single-molecule detection technology to accurately quantify proteins, DNA, and RNA molecules in biological samples, allowing scientists and clinicians to gain new insights into disease mechanisms and improve disease diagnosis and treatment.
Quanterix Corp's technology has a wide range of applications, including oncology, neurology, cardiology, infectious diseases, inflammation, and autoimmune diseases.
The company collaborates with leading academic institutions, pharmaceutical companies, and diagnostic companies to validate its technology and develop innovative diagnostic assays.
Quanterix Corp has received numerous awards for its technology, including being named a Technology Pioneer by the World Economic Forum, one of the 50 Smartest Companies by MIT Technology Review, and one of the Top 10 Innovations of the Year by The Scientist magazine.
The company is headquartered in Billerica, Massachusetts, and has offices and subsidiaries in Europe and Asia.
Company Address: 900 Middlesex Turnpike Billerica 1821 MA
Company Phone Number: 301-9400 Stock Exchange / Ticker: NASDAQ QTRX
|
1.85% 
70.5 %